Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 110 P517 | DOI: 10.1530/endoabs.110.P517

ECEESPE2025 Poster Presentations Endocrine Related Cancer (76 abstracts)

Six unrelated italian kindreds with multiple endocrine neoplasia type 4 (MEN4) harboring variants of the CDKN1B gene

Elena Pardi 1 , Chiara Sardella 2 , Simone Della Valentina 1 , Laura Pierotti 1 , Anna Dal Lago 1 , Angela Michelucci 3 , Maria Adelaide Caligo 3 , Claudio Marcocci 1 & Filomena Cetani 1


1University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy; 2University Hospital of Pisa, Endocrine Unit 2, Pisa, Italy; 3University Hospital of Pisa, Laboratory of Molecular Genetics, Pisa, Italy


JOINT3281

Multiple endocrine neoplasia type 4 (MEN4), caused by heterozygous inactivating mutations of the CDKN1B gene, is a rare hereditary syndrome presenting a combination of multiple endocrine tumors. It is characterized by a great overlap with MEN1 syndrome, having primary hyperparathyroidism (PHPT) the highest penetrance. Other tumors including renal, gonadal, adrenal, and thyroid tumors may be present. Here we describe six new MEN4 kindreds. The germline DNA of all the probands underwent next generation sequencing using a panel of PHPT-related genes. The proband of family 1 was a 55-yr woman with PHPT and bilateral adrenal lesions. An inferior left parathyroid adenoma was removed leading to the remission of PHPT after 21 months follow-up. The proband and her two siblings, both having mild elevated PTH levels and normocalcemia, carried a CDKN1B variant (c. 482C>G, p. Ser161Cys). The proband of family 2 was a 29-yr woman with PHPT and uterine myoma. An inferior left parathyroid adenoma was excised, resulting in the remission of PHPT after 43 months of follow-up. The proband and her mother affected by PHPT carried the CDKN1B variant c. 356T>C, p. Ile119Thr. The proband of family 3 was a 42-yr woman with PHPT, pancreatic neuroendocrine tumor (PNET) and single adrenal lesion. Inferior and superior right parathyroid adenomas were removed, leading to the remission of PHPT after 45 months of follow-up. The proband’s mother was also affected by PHPT and is under surveillance. Both carried the CDKN1B variant c. 358G>A, p. Gly120Arg. The proband of family 4 was a 60-yr woman with PHPT, a non-functioning PNET, uterine myoma, bilateral adrenal hyperplasia, and melanoma. An inferior right parathyroid adenoma was removed leading to the remission of PHPT after 9 months of follow-up. She carried the CDKN1B variant c. 230A>C, p. Gln77Pro. The proband’s sister, affected by PHPT, and the healthy nephew carried the same variant. The proband of family 5 was a 30-yr woman with PHPT. A superior left parathyroid adenoma was removed leading to the remission of PHPT after 66 months of follow-up. The proband and the healthy mother carried the CDKN1B variant c. 470C>T, pThr157Ile. The proband of family 6 was a 59-yr woman with recurrent PHPT due to right inferior, and left superior and inferior parathyroid adenoma. She carried the CDKN1B variant c. 274C>T, p. Pro92Ser. The CDKN1B variants segregate with the disease in all kindreds although they were classified as variants of unknown significance. Their functional consequences remain to be established.

Volume 110

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

European Society of Endocrinology 
European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches